We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02491268
Recruitment Status : Completed
First Posted : July 8, 2015
Last Update Posted : December 4, 2020
Sponsor:
Information provided by (Responsible Party):
Masafumi Ihara, National Cerebral and Cardiovascular Center

Brief Summary:

Epidemiological, clinicopathological and animal studies show that vascular disease in various forms contributes to cognitive decline. Increasing age is the strongest risk for dementia irrespective of whether it results from a vascular etiology or neurodegenerative disease processes such as in Alzheimer's disease (AD). AD and vascular cognitive impairment, the two most common causes of dementia, represent two extremes of a spectrum of disorders; however, a number of entities, which possess varying degrees of neurodegenerative and vascular pathologies, occur in between. The pure forms of the disorders are preferred for convenience to label, treat or manage but conditions within the spectrum are the norm rather than the exception as dementia advances. Therefore, combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia is a promising approach for the treatment of dementia in the elderly.

Cilostazol acts as an antiplatelet agent and has other pleiotropic effects based on phosphodiesterase-3-dependent mechanisms. Increasing evidence suggests that cilostazol offers endothelial protection, via pleiotropic effects. Intriguingly, cilostazol has been shown to decrease amyloid beta (Abeta) accumulation and protect Abeta-induced cognitive deficits in an experimental model. In a pilot study of 10 patients with moderate AD (mean MMSE score, 11.9 points) who received donepezil, cilostazol add-on treatment for 5-6 months demonstrated significantly increased MMSE score in comparison to baseline. Moreover, cilostazol was shown to be effective in preventing cognitive decline in patients with AD with cerebrovascular diseases, mild cognitive impairment (MCI), and mild dementia who received donepezil.

These results highlight the need for a comprehensive prospective cohort study to analyze the effect of cilostazol on the preservation of cognitive function in patients with early-stage cognitive impairment, namely MCI.


Condition or disease Intervention/treatment Phase
Mild Cognitive Impairment Drug: Cilostazol Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 166 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Trial of Cilostazol for Prevention of Conversion From Mild Cognitive Impairment to Dementia
Actual Study Start Date : May 1, 2015
Actual Primary Completion Date : August 14, 2020
Actual Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dementia
Drug Information available for: Cilostazol

Arm Intervention/treatment
Experimental: Cilostazol 50mg B.I.D.

After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.

Protocol treatment defines as follows;

Investigational Treatment:

Cilostazol 50mg B.I.D. p.o. 96 Weeks

Drug: Cilostazol
Placebo Comparator: Placebo B.I.D.

After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.

Protocol treatment defines as follows;

Comparative Treatment:

Placebo B.I.D. p.o. 96 Weeks

Drug: Placebo



Primary Outcome Measures :
  1. Change from baseline in Mini Mental State Examination (MMSE) [ Time Frame: 96 weeks ]

Secondary Outcome Measures :
  1. Conversion from MCI to All-cause Dementia [ Time Frame: up to 96 weeks ]
    Dementia is diagnosed clinically when the patient meets core clinical criteria for dementia with reference to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.

  2. Cognitive Decline on Clinical dementia rating-sum of boxes (CDR-SB) [ Time Frame: baseline, 48 weeks, and 96 weeks ]
  3. Cognitive Decline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) 14 [ Time Frame: baseline, 48 weeks, and 96 weeks ]
  4. Cognitive Decline on Logical Memory subtest of the Wechsler Memory Scale-Revised (WMS-R) [ Time Frame: baseline, 48 weeks, and 96 weeks ]
  5. Functional Decline on Alzheimer's disease Cooperative Study scale for activities of daily living in MCI (ADCS-MCI-ADL) [ Time Frame: baseline, 48 weeks, and 96 weeks ]
  6. Hippocampal volume [ Time Frame: baseline and 96 weeks ]
    Magnetization prepared rapid acquisition with gradient echo is used to assess hippocampal volume.


Other Outcome Measures:
  1. Cognitive Decline on Free and Cued Selective Reminding Test (FCSRT) [ Time Frame: baseline, 48 weeks, and 96 weeks ]
  2. Cognitive Decline on Trail making test (TMT) [ Time Frame: baseline, 48 weeks, and 96 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 84 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age between 55-84 (inclusive)
  2. Study partner who sufficiently knows the daily life of the patient
  3. Patients with MCI who satisfy the core clinical criteria of National Institute for Aging-Alzheimer Association for MCI (nearly equivalent to mild neurocognitive disorder in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) and who also satisfy the following three criteria:

    i) Memory complaint by subject or study partner Type I: Memory complaint by subject that is verified by a study partner Type II: Otherwise, memory complaint by study partner with the evidence of memory impairment Note) Memory complaint by subject that is not verified by study partner will be excluded.

    ii) Mini-Mental State Examination (MMSE) scores between 22 and 28 (inclusive) iii) Clinical Dementia Rating (CDR) = 0.5

  4. Written informed consent provided for study participation

Exclusion Criteria:

  1. Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy, epilepsy, multiple sclerosis, cerebral infection, or subsequent complication caused by head trauma.
  2. Findings of multiple infarction, brain tumor, or subdural hematoma on MRI performed within 48 weeks before provisional registration.
  3. Contraindications for MRI such as magnetic body or metal.
  4. History of major depression or bipolar disorder within 48 weeks before provisional registration, alcohol or other substance abuse within 96 weeks before provisional registration, other diseases or unstable conditions.
  5. Poorly controlled diabetes mellitus (HbA1c>9.0%).
  6. Cognitive impairment due to deficiency of vitamin B12 or folate.
  7. Neurosyphilis.
  8. Cognitive impairment due to thyroid function abnormality.
  9. Psychoactive drugs within 4 weeks before provisional registration.
  10. Oral anticoagulants within 4 weeks before provisional registration.
  11. Double antiplatelet therapy (cf. Aspirin, Clopidogrel but not Cilostazol) within 4 weeks before provisional registration.
  12. Poorly controlled diabetes mellitus treated with insulin within 4 weeks before provisional registration.
  13. Episode of hypoglycemic attack with loss of consciousness within 4 weeks before provisional registration.
  14. Anti-dementia drugs within 4 weeks before provisional registration.
  15. Participation in any other new drug study for Alzheimer's disease.
  16. Current bleeding or bleeding disorders.
  17. Congestive heart failure.
  18. Coronary artery stenosis.
  19. Sustained high blood pressure within 2 weeks before provisional registration.
  20. History of drug hypersensitivity to Cilostazol.
  21. The subject or the subject's spouse pregnant or breast-feeding at the time of provisional registration.
  22. Difficulty in neuropsychological tests due to hearing or visual impairment.
  23. Considered by the principal investigator to be ineligible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02491268


Locations
Layout table for location information
Japan
National Cerebral and Cardiovascular Center
Suita, Osaka, Japan, 564-8565
Sponsors and Collaborators
National Cerebral and Cardiovascular Center
Layout table for additonal information
Responsible Party: Masafumi Ihara, Chief Physician (Head of Neurology), National Cerebral and Cardiovascular Center
ClinicalTrials.gov Identifier: NCT02491268    
Other Study ID Numbers: TRINEU1321
First Posted: July 8, 2015    Key Record Dates
Last Update Posted: December 4, 2020
Last Verified: December 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders
Cilostazol
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Vasodilator Agents
Neuroprotective Agents
Protective Agents
Phosphodiesterase 3 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors